Home Newsfeeds Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208

Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $208.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $208.

CorMedix Announces Commercial Agreement With Top Tier Dialysis Provider For The Supply Of DefenCath

By Benzinga Newsdesk

May 28, 8:43 AM

CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply

CRMD

Inquiry Into Mastercard’s Competitor Dynamics In Financial Services Industry

By Benzinga Insights

April 15, 11:00 AM

In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for…

Delta Air Lines, Msci And This Japanese Stock On CNBC’s ‘Final Trades’

By Priya Nigam

February 28, 9:50 AM

On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust named Fanuc ADR (OTC: FANUY), which is the no. 1 global manufacturer of industrial robots.

DAL

L3Harris Likely To Report Decline In Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

By Lisa Levin

July 26, 9:08 AM

L3Harris Technologies, Inc. (NYSE: LHX) is expected to report its second-quarter financial results, after the closing bell on July 26, 2023.

LHX

Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $208

Related Posts

CorMedix Announces Commercial Agreement With Top Tier Dialysis Provider For The Supply Of DefenCath

Inquiry Into Mastercard’s Competitor Dynamics In Financial Services Industry

Delta Air Lines, Msci And This Japanese Stock On CNBC’s ‘Final Trades’

L3Harris Likely To Report Decline In Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts